Obesity: Classification, Causes and the NICE Treatment Ladder
Key points
- Obesity: excess body fat sufficient to increase health risk, classified in adults by BMI: overweight 25-29.9, obese class I 30-34.9, class II 35-39.9, class III (morbid) 40 or above, all in kg/m2.
- BMI's limitations: does not distinguish fat from muscle and is less accurate in very muscular individuals. Lower BMI and waist circumference thresholds apply in South Asian and other high-risk ethnic groups.
- Waist circumference: a useful adjunct measure of central (visceral) adiposity, which carries greater metabolic risk than fat distributed elsewhere.
- Aetiology: ultimately an energy imbalance, but driven by genetic, endocrine (e.g. hypothyroidism, Cushing's syndrome), psychological, environmental and pharmacological (e.g. antipsychotics, insulin, sulfonylureas) contributors, and rarely monogenic causes.
- Comorbidities: span nearly every system - type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, MASLD, osteoarthritis, several cancers, infertility/PCOS, VTE and psychological impact.
- Management ladder: behavioural/lifestyle intervention for everyone; pharmacotherapy (orlistat, GLP-1 receptor agonists) for selected patients; bariatric surgery for severe obesity after non-surgical measures have failed.
- Bariatric surgery indications: BMI 40 or above, or 35 or above with significant obesity-related comorbidity, generally after structured non-surgical measures have been tried.
- Post-surgical care: lifelong nutritional monitoring and supplementation (e.g. B12, iron, calcium, vitamin D) are essential, particularly after malabsorptive procedures.
Introduction
Obesity is a chronic condition characterised by excess body fat sufficient to have an adverse effect on health. It is now one of the commonest problems seen across every area of medicine, both as a presenting concern and as a major driver of comorbidity in patients presenting with something else.
Around two-thirds of adults in the UK are living with overweight or obesity, and prevalence continues to rise. It is best understood not as a failure of willpower but as a chronic relapsing condition shaped by biology, environment and behaviour together, which is the framing NICE and most modern guidelines now use.
Classification
Body mass index
BMI = weight (kg) / height (m)^2, and remains the standard population-level classification tool because it is simple, cheap and reproducible.1
| Category | BMI (kg/m2) |
|---|---|
| Underweight | Below 18.5 |
| Healthy weight | 18.5-24.9 |
| Overweight | 25.0-29.9 |
| Obese class I | 30.0-34.9 |
| Obese class II | 35.0-39.9 |
| Obese class III (morbid obesity) | 40.0 or above |
Waist circumference
Waist circumference is a useful adjunct that directly reflects central (visceral) adiposity, which carries substantially greater metabolic and cardiovascular risk than fat distributed peripherally, for a given BMI.
| Risk level | Men | Women |
|---|---|---|
| Increased risk | 94 cm or above | 80 cm or above |
| Substantially increased risk | 102 cm or above | 88 cm or above |
As with BMI, lower thresholds apply in South Asian populations given the same increased risk at a lower absolute measurement.
Aetiology
At the most basic level, obesity results from energy intake exceeding energy expenditure over a sustained period - but this final common pathway is shaped by numerous contributing factors, and identifying them matters for both management and, occasionally, for excluding a treatable secondary cause.
| Category | Examples |
|---|---|
| Genetic | Polygenic susceptibility is the commonest contributor and interacts strongly with environment; family and twin studies show substantial heritability of body weight |
| Obesogenic environment | Easy availability of energy-dense, highly processed food, large portion sizes, sedentary occupations and leisure activities, reduced active transport |
| Psychological / behavioural | Emotional or binge eating, disordered sleep, stress, and obesity as a consequence or driver of low mood and mental illness |
| Endocrine causes (uncommon but worth excluding) | Hypothyroidism, Cushing's syndrome, and rarely growth hormone deficiency or hypothalamic damage (e.g. after surgery or radiotherapy for a pituitary or hypothalamic tumour) |
| Drugs | Antipsychotics (especially olanzapine, clozapine), insulin and sulfonylureas, some antidepressants (e.g. mirtazapine, some tricyclics), corticosteroids, sodium valproate, some antiepileptics, and older-generation antihistamines |
| Monogenic obesity (rare, but classically examined) | Severe early-onset obesity with hyperphagia - leptin deficiency, leptin receptor deficiency, and melanocortin-4-receptor (MC4R) deficiency, the commonest monogenic cause |
| Syndromic | Prader-Willi syndrome and other genetic syndromes with associated developmental features |
Complications and comorbidities
Obesity is associated with adverse effects across nearly every organ system, which is why it is treated as a chronic disease in its own right rather than simply a risk factor.
| System | Complications |
|---|---|
| Metabolic | Type 2 diabetes, prediabetes, dyslipidaemia, metabolic syndrome |
| Cardiovascular | Hypertension, ischaemic heart disease, heart failure, stroke, venous thromboembolism |
| Respiratory | Obstructive sleep apnoea, obesity hypoventilation syndrome, worsened asthma control |
| Hepatic | Metabolic dysfunction-associated steatotic liver disease (MASLD), progressing to steatohepatitis, fibrosis and cirrhosis in a minority |
| Musculoskeletal | Osteoarthritis (particularly knees and hips), back pain, gout |
| Reproductive | Polycystic ovary syndrome, subfertility and infertility in both sexes, erectile dysfunction, adverse pregnancy outcomes (gestational diabetes, pre-eclampsia, caesarean delivery) |
| Oncological | Increased risk of endometrial, breast (post-menopausal), colorectal, oesophageal (adenocarcinoma), renal, pancreatic and gallbladder cancer |
| Psychological | Depression, anxiety, reduced quality of life, and the substantial impact of weight stigma and discrimination |
| Surgical / anaesthetic | Increased risk of difficult airway, wound infection, VTE and prolonged recovery; often affects eligibility for elective procedures |
| Other | Gastro-oesophageal reflux disease, urinary incontinence, skin conditions (intertrigo), reduced mobility and functional impairment |
Assessment
- BMI and waist circumference, using ethnicity-appropriate thresholds
- Screen for comorbidity - blood pressure, fasting glucose or HbA1c, lipid profile, liver function, and ask about symptoms of obstructive sleep apnoea (snoring, witnessed apnoeas, daytime somnolence - consider the Epworth Sleepiness Scale)
- Assess readiness and barriers to change, dietary pattern, physical activity level, and psychological factors including any history of disordered eating
- Medication review for obesogenic drugs that could be substituted
- Brief screen for secondary causes where clinically suggested (TFTs; features of Cushing's syndrome)
Management
NICE describes a stepped approach, escalating from behavioural support through pharmacotherapy to surgery, with each step building on rather than replacing the one before.2
Step 1: behavioural and lifestyle intervention
This is the foundation for everyone, regardless of whether drug treatment or surgery is later added.
- Dietary change - a reduced-calorie diet tailored to the individual; no single diet is mandated, and adherence matters more than the specific approach chosen
- Increased physical activity - at least 150 minutes of moderate-intensity activity a week, built up gradually
- Behavioural therapy - goal setting, self-monitoring, stimulus control and relapse prevention strategies, often delivered through structured multicomponent programmes (e.g. NHS-commissioned tier 2/3 weight management services)
- Realistic goal-setting - a sustained 5-10% weight loss produces clinically meaningful improvement in comorbidity even without reaching an ideal BMI
Step 2: pharmacotherapy
Considered alongside continued lifestyle support, generally where lifestyle measures alone have not achieved sufficient weight loss.
| Drug | Mechanism | Key points |
|---|---|---|
| Orlistat | Inhibits pancreatic and gastric lipase, reducing intestinal fat absorption by around 30% | NICE criteria historically included BMI 28 or above with a risk factor, or 30 or above alone. Side effects are gastrointestinal - oily stools, faecal urgency and flatulence, worsened by a high-fat meal. Reduces absorption of fat-soluble vitamins. |
| Liraglutide (GLP-1 receptor agonist) | Incretin analogue - suppresses appetite via central and gastric mechanisms, slows gastric emptying | Daily injection, licensed for weight management at a higher dose than used in diabetes. NICE requires specialist weight management service involvement and, generally, a BMI of 35 or above (30 or above with comorbidity). |
| Semaglutide (GLP-1 receptor agonist) | As above, longer acting | Weekly injection. NICE-approved for weight management with similar eligibility criteria, time-limited course (typically up to 2 years) within specialist services. |
| Tirzepatide (dual GIP/GLP-1 receptor agonist) | Combined incretin agonism, producing greater average weight loss than GLP-1 agonism alone in trials | Weekly injection. Increasingly used under similar NICE-defined eligibility pathways. |
Step 3: bariatric surgery
The most effective intervention for severe obesity, producing substantially greater and more durable weight loss than lifestyle or drug treatment alone, and capable of inducing remission of type 2 diabetes.
| Criterion | Detail |
|---|---|
| BMI 40 or above | Eligible regardless of comorbidity |
| BMI 35-39.9 | Eligible if there is a significant obesity-related comorbidity that could improve with weight loss (e.g. type 2 diabetes, hypertension, obstructive sleep apnoea) |
| BMI 30-34.9 with recent-onset type 2 diabetes | Expedited assessment recommended, since the metabolic benefit is greatest early in the disease course |
| Lower thresholds for people of Asian family origin | As above, reflecting increased risk at a lower BMI |
| General prerequisite | Non-surgical measures have been tried for a sustained period without adequate benefit, the person is fit for anaesthesia and surgery, and they are committed to long-term follow-up |
| Procedure | Mechanism | Notes |
|---|---|---|
| Adjustable gastric band | Restrictive - an inflatable band around the upper stomach limits intake | Least invasive and reversible, but produces the least weight loss and has a high long-term revision/removal rate |
| Sleeve gastrectomy | Restrictive - removes most of the stomach, creating a narrow tube; also reduces ghrelin secretion, suppressing appetite | Now the commonest procedure in the UK; good weight loss with a simpler operation than bypass |
| Roux-en-Y gastric bypass | Restrictive and malabsorptive - a small gastric pouch is connected directly to the mid-jejunum, bypassing most of the stomach and duodenum; also produces marked incretin (GLP-1) changes | Greatest average weight loss and highest rate of type 2 diabetes remission, but the highest complication rate and greatest risk of nutritional deficiency |
| Biliopancreatic diversion with duodenal switch | Predominantly malabsorptive | Reserved for the most severe obesity; greatest weight loss but also the greatest risk of malnutrition, used less commonly |
Red flags
Prognosis
Obesity is a chronic, relapsing condition, and sustained weight loss through lifestyle measures alone is difficult to maintain for most people over the long term - regain is common and should be anticipated and planned for rather than treated as a failure. Pharmacotherapy improves outcomes while treatment continues but weight regain typically follows discontinuation, reinforcing that these drugs are used within a long-term management plan rather than as a short course.
Bariatric surgery produces the most durable outcomes, with substantial and largely sustained weight loss at 10 years in most patients, alongside high rates of remission or major improvement in type 2 diabetes, hypertension, obstructive sleep apnoea and quality of life. Nonetheless, a minority experience weight regain over subsequent years, and lifelong follow-up, nutritional monitoring and psychological support remain necessary regardless of which treatment pathway is used.
References
- NICE Clinical Knowledge Summaries. Obesity. Available here
- NICE CG189. Obesity: identification, assessment and management. 2014, updated 2023. Available here
- NICE TA664. Semaglutide for managing overweight and obesity. 2023. Available here
- NICE TA875. Tirzepatide for managing overweight and obesity. 2023. Available here
- BNF. Orlistat, liraglutide and semaglutide - indications and dosing. Available here
- World Health Organization. Body mass index and waist circumference thresholds for Asian populations. Available here
This article is written for revision and education. It is not clinical guidance and must not be used to make decisions about the care of a patient. Always check current NICE guidance and local protocols.